COST-EFFECTIVENESS OF NAVIGATED RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA IN CHINA

被引:3
|
作者
Lai, Yizhen [1 ]
Li, Kai [2 ]
Li, Junbo [3 ]
Liu, Sheena Xin [4 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510275, Guangdong, Peoples R China
[3] Philips Res Asia, Shanghai 200233, Peoples R China
[4] Philips Res North Amer, Briarcliff Manor, NY 10510 USA
关键词
Cost-effectiveness; Real-time Virtual Sonography; Hepatocellular Carcinoma; Radiofrequency Ablation; Markov model; TIME VIRTUAL SONOGRAPHY; HEPATIC RESECTION; SURGICAL RESECTION; CT;
D O I
10.1017/S0266462314000452
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Real-time virtual sonography (RVS) is a promising navigation technique for percutaneous radiofrequency ablation (RFA) treatment, especially in ablating nodules poorly visualized on conventional ultrasonography (US). However, its cost-effectiveness has not been established. The purpose of this study is to evaluate the cost-effectiveness of RVS navigated RFA (RVS-RFA) relative to US guided RFA (US-RFA) in patients with small hepatocellular carcinoma (HCC) in China, from the modified societal perspective. Methods: A state-transition Markov model was created using TreeAge Pro (TM) 2012. The parameters used in the model, including natural history of HCC patients, procedure efficacy and related costs, were obtained from a systematic search of literature through PubMed, EMBASE, and Science Citation Index databases. The simulated cohort was patients with solitary, small HCC (<3 cm in diameter) and Child-Pugh class A or B, whose tumors are poorly visualized in B-mode US but clearly detectable by CT or MRI. Results: In this cohort of difficult cases, RVS-RFA was a preferred strategy saving 2,467 CNY ($392) throughout the patient's life while gaining additional 1.4 QALYs compared with conventional US guidance. The results were sensitive to the efficacy of US-RFA and RVS-RFA including complete ablation rate and local recurrence rate, the median survival for patients with progressive HCC, the probability of performing RFA for recurrent HCC, and the cost of RVS navigation, disposable needle or hospitalization. Conclusions: RVS-RFA is a dominant strategy for patients with small HCC unidentifiable in B-mode US, in terms of cost savings and QALYs gained, relative to the conventional US-guided method.
引用
收藏
页码:400 / 408
页数:9
相关论文
共 50 条
  • [21] Radiofrequency ablation for hepatocellular carcinoma
    McGahan, JP
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (05) : 853 - 854
  • [22] Radiofrequency Ablation of hepatocellular Carcinoma
    Widmann, Gerlig
    Schullian, Peter
    Bale, Reto
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2013, 163 (5-6) : 132 - 136
  • [23] Radiofrequency Ablation of Hepatocellular Carcinoma
    Chiou, Yi-You
    Chou, Yi-Hong
    JOURNAL OF MEDICAL ULTRASOUND, 2008, 16 (04) : 272 - 284
  • [24] Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Ramtohul, Toulsie
    Vilgrain, Valerie
    Soubrane, Olivier
    Bouattour, Mohamed
    Luciani, Alain
    Kobeiter, Hicham
    Mule, Sebastien
    Tacher, Vania
    Laurent, Alexis
    Amaddeo, Giuliana
    Regnault, Helene
    Bulsei, Julie
    Nault, Jean-Charles
    Nahon, Pierre
    Durand-Zaleski, Isabelle
    Seror, Olivier
    CANCERS, 2022, 14 (11)
  • [25] COST-EFFECTIVENESS OF HEPATIC RESECTION VERSUS PERCUTANEOUS ABLATION FOR HEPATOCELLULAR CARCINOMA WITHIN THE MILAN CRITERIA
    Cucchetti, A.
    Piscaglia, F.
    Cescon, M.
    Colecchia, A.
    Bolondi, L.
    Pinna, A. D.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S112 - S113
  • [26] COST-EFFECTIVENESS OF RADIOFREQUENCY CATHETER ABLATION IN THE TREATMENT OF SYMPTOMATIC SUPRAVENTRICULAR TACHYARRHYTHMIAS
    KERTES, PJ
    KALMAN, JM
    TONKIN, AM
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1993, 23 (04): : 433 - 436
  • [27] Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness
    Yuen, MF
    Lai, CL
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1463 - 1467
  • [28] COST-EFFECTIVENESS OF LENVATINIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE UK
    Simon, C.
    Trueman, D.
    Hancock, E.
    Hellmund, C.
    Pan, J. J.
    de Rosendo, J. M.
    Webb, T.
    VALUE IN HEALTH, 2019, 22 : S478 - S478
  • [29] Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma
    Kong, Qing-Feng
    Jiao, Jun-Bo
    Chen, Qian-Qian
    Li, Long
    Wang, Dong-Guang
    Lv, Bin
    TUMOR BIOLOGY, 2014, 35 (03) : 2655 - 2659
  • [30] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Guan, Haijing
    Wang, Chunping
    Zhao, Zhigang
    Han, Sheng
    ADVANCES IN THERAPY, 2022, 39 (07) : 3334 - 3346